Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 1;6(4):495-503.
doi: 10.1001/jamaoncol.2019.6143.

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Annette M Molinaro  1 , Shawn Hervey-Jumper  1 , Ramin A Morshed  1 , Jacob Young  1 , Seunggu J Han  2 , Pranathi Chunduru  1 , Yalan Zhang  1 , Joanna J Phillips  1   3 , Anny Shai  1 , Marisa Lafontaine  4 , Jason Crane  4 , Ankush Chandra  1 , Patrick Flanigan  1 , Arman Jahangiri  5 , Gino Cioffi  6 , Quinn Ostrom  7 , John E Anderson  6   8 , Chaitra Badve  6   8 , Jill Barnholtz-Sloan  6   9 , Andrew E Sloan  6   10 , Bradley J Erickson  11 , Paul A Decker  11 , Matthew L Kosel  11 , Daniel LaChance  11 , Jeanette Eckel-Passow  11 , Robert Jenkins  11 , Javier Villanueva-Meyer  4 , Terri Rice  1 , Margaret Wrensch  1 , John K Wiencke  1 , Nancy Ann Oberheim Bush  1   12 , Jennie Taylor  1   12 , Nicholas Butowski  1 , Michael Prados  1 , Jennifer Clarke  1   12 , Susan Chang  1 , Edward Chang  1 , Manish Aghi  1 , Philip Theodosopoulos  1 , Michael McDermott  1 , Mitchel S Berger  1
Affiliations

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Annette M Molinaro et al. JAMA Oncol. .

Erratum in

  • Error in Institution Name in the Text.
    [No authors listed] [No authors listed] JAMA Oncol. 2020 Mar 1;6(3):444. doi: 10.1001/jamaoncol.2020.0360. JAMA Oncol. 2020. PMID: 32163171 Free PMC article. No abstract available.

Abstract

Importance: Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively. Although maximal resection of contrast-enhanced (CE) tumor is associated with longer survival, the prognostic importance of maximal resection within molecular subgroups and the potential importance of resection of non-contrast-enhanced (NCE) disease is poorly understood.

Objective: To assess the association of resection of CE and NCE tumors in conjunction with molecular and clinical information to develop a new road map for cytoreductive surgery.

Design, setting, and participants: This retrospective, multicenter cohort study included a development cohort from the University of California, San Francisco (761 patients diagnosed from January 1, 1997, through December 31, 2017, with 9.6 years of follow-up) and validation cohorts from the Mayo Clinic (107 patients diagnosed from January 1, 2004, through December 31, 2014, with 5.7 years of follow-up) and the Ohio Brain Tumor Study (99 patients with data collected from January 1, 2008, through December 31, 2011, with a median follow-up of 10.9 months). Image accessors were blinded to patient groupings. Eligible patients underwent surgical resection for newly diagnosed glioblastoma and had available survival, molecular, and clinical data and preoperative and postoperative magnetic resonance images. Data were analyzed from November 15, 2018, to March 15, 2019.

Main outcomes and measures: Overall survival.

Results: Among the 761 patients included in the development cohort (468 [61.5%] men; median age, 60 [interquartile range, 51.6-67.7] years), younger patients with IDH-wild-type tumors and aggressive resection of CE and NCE tumors had survival similar to that of patients with IDH-mutant tumors (median overall survival [OS], 37.3 [95% CI, 31.6-70.7] months). Younger patients with IDH-wild-type tumors and reduction of CE tumor but residual NCE tumors fared worse (median OS, 16.5 [95% CI, 14.7-18.3] months). Older patients with IDH-wild-type tumors benefited from reduction of CE tumor (median OS, 12.4 [95% CI, 11.4-14.0] months). The results were validated in the 2 external cohorts. The association between aggressive CE and NCE in patients with IDH-wild-type tumors was not attenuated by the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase.

Conclusions and relevance: This study confirms an association between maximal resection of CE tumor and OS in patients with glioblastoma across all subgroups. In addition, maximal resection of NCE tumor was associated with longer OS in younger patients, regardless of IDH status, and among patients with IDH-wild-type glioblastoma regardless of the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase. These conclusions may help reassess surgical strategies for individual patients with newly diagnosed glioblastoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Phillips reported receiving grants from the National Institutes of Health/National Cancer Institute (NIH/NCI) during the conduct of the study. Dr Badve reported receiving grants and intellectual property in the form of patents and royalties from the Clinical and Translational Science Center and Case Cancer Center outside the submitted work. Dr Wrensch reported receiving grants from NCI and funding from private donors (known as the Loglio Collective) to the UCSF Neurological Surgery Department during the conduct of the study. Dr Taylor reported receiving grants from Agios Pharmaceuticals, Inc, Bristol-Myers Squibb, and AbbVie, Inc, outside the submitted work. Dr Prados reported receiving grants from Brain Tumor SPORE during the conduct of the study. Dr Clarke reported receiving grants and personal fees from Agios Pharmaceuticals, Inc, Genentech/Roche, Merck & Co, and Novartis International AG outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Data Flow Diagram for the UCSF Development Cohort
IDH indicates isocitrate dehydrogenase gene 1 or 2; MGMT, promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase.
Figure 2.
Figure 2.. Recursive Partitioning Analysis (RPA) for Post-2005/IDH-Known Subset
Includes 434 patients. Four risk groups were determined by RPA based on adjuvant temozolomide treatment after surgery, isocitrate dehydrogenase gene 1 or 2 (IDH) status, age at diagnosis, and residual non–contrast-enhancing (NCE) tumor after surgery. Groups are denoted by numbers 1 through 4. Group 4 is the combination of 2 subgroups: temozolomide-treated patients with IDH-mutant tumors and temozolomide-treated patients aged 65 years or younger with IDH–wild-type tumors with no greater than 5.4 mL of NCE residual tumor.
Figure 3.
Figure 3.. Kaplan-Meier Curves for Overall Survival for 4 Risk Groups
Groups are described in Figure 2. A, Includes patients in the post-2005 isocitrate dehydrogenase gene 1 or 2 status (IDH)-known (n = 434). For group 1, median overall survival was 3.6 (95% CI, 2.6-5.4) months (univariable hazard ratio [HR], 3.31 [95% CI, 2.31-4.74]; P < .001); group 2, 12.4 (95% CI, 11.4-14.0) months (univariable HR, 1.45 [95% CI, 1.15-1.83]; P = .001); group 3, 16.5 (95% CI, 14.7-18.3) months (univariable HR, 1 [reference]); and group 4, 37.3 (95% CI, 31.6-70.7) months (univariable HR, 0.36 [95% CI, 0.25-0.51]; P < .001). B, Includes groups 1 to 3 (gray) and the 2 subgroups in group 4. Group 4A represents the temozolomide-treated patients with IDH–wild-type tumors who were younger than 65 years and with no more than 5.4 mL of non–contrast-enhancing residual tumor (median overall survival, 31.7 [95% CI, 22.2-43.9] months); group 4B, the temozolomide-treated patients with IDH-mutant tumors (median overall survival, 78.4 [95% CI, 35.1-not applicable] months). C, Includes Mayo Clinic (n = 107) and Ohio Brain Tumor Study (n = 99) patients with glioblastoma. Median overall survival for group 1 was 3.8 (95% CI, 2.4-4.6) months (univariable HR, 6.17 [95% CI, 4.08-9.33]; P < .001); group 2, 12.8 (95% CI, 10.9-14.6) months (univariable HR, 1.58 [95% CI, 1.11-2.25]; P = .01); group 3, 17.5 (95% CI, 15.3-22.5) months (univariable HR, 1 [reference]); and group 4, 32.4 (95% CI, 21.7-not applicable) months (univariable HR, 0.54 [95% CI, 0.31-0.94]; P = .03).
Figure 4.
Figure 4.. Proposed Surgical Strategy for Newly Diagnosed Glioblastoma
Strategy consists of maximal resection of the contrast-enhanced (CE) tumors for all patients with the additional maximum resection of the non–contrast-enhanced (NCE) tumors for patients younger than 65 years, when safely feasible.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Louis DN, Perry A, Reifenberger G, et al. . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405-417. doi:10.1038/s41582-019-0220-2 - DOI - PMC - PubMed
    1. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5(3):198-206. doi:10.1007/s11910-005-0047-7 - DOI - PubMed
    1. McGirt MJ, Chaichana KL, Gathinji M, et al. . Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162. doi:10.3171/2008.4.17536 - DOI - PubMed
    1. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3-8. doi:10.3171/2011.2.JNS10998 - DOI - PubMed

MeSH terms